Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injection kit for intravenous use. It enables myocardial perfusion imaging to assess coronary artery disease in adult patients, providing clinicians with functional information on regional blood flow. The product is authorized in the European Union and is used under physician supervision for diagnostic cardiac procedures.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with strict quality assurance and regulatory support.

Myoview (tetrofosmin) is used in cardiac imaging to evaluate myocardial blood flow.

Myocardial perfusion imaging (SPECT): Provides visual assessment of regional myocardial blood flow to detect perfusion defects. Coronary artery disease evaluation: Helps identify areas of reduced perfusion indicative of obstructive coronary lesions. Myocardial viability assessment: Differentiates viable from scarred myocardium to guide revascularization decisions.

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm, or anaphylaxis requiring immediate medical attention. - Cardiac arrhythmia: rare occurrence of rhythm disturbances during imaging. - Radiation exposure: low‑level ionizing radiation with cumulative risk, monitored per regulatory limits.

When using Myoview, clinicians should observe specific precautions to ensure patient safety and product integrity.

- Patient selection: verify indication and assess for known hypersensitivity to tetrofosmin or similar agents. - Renal function: consider reduced clearance in severe renal impairment. - Thyroid status: avoid use in patients with uncontrolled hyperthyroidism due to iodine content. - Concurrent imaging agents: schedule sufficient interval after other radiopharmaceuticals to prevent interference. - Pregnancy and lactation: weigh potential risks versus benefits; use only if clearly justified. - Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture and light.

Myoview may interact with certain drugs or substances that affect its distribution, clearance, or imaging interpretation.

Major Interactions (Avoid): - Beta‑blockers: may alter myocardial blood flow and affect image interpretation. - Calcium channel blockers: can modify coronary vasomotor tone, influencing tracer uptake. - Thyroid hormones: excess may compete with radiotracer uptake.

Moderate Interactions (Monitor Closely): - Other radiopharmaceuticals: overlapping radiation dose requires timing adjustments. - Contrast agents used in CT: may interfere with subsequent SPECT imaging if administered too soon. - Caffeine‑containing products: can affect myocardial perfusion and should be avoided before the test.